- May 8, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
BiCNU, Gliadel
Synonyms :
BCNU, Bischloroethyl nitrosourea, Carmustina, Carmustine, Carmustinum
Class :
Class: Antineoplastic agents and Subclass: Nitrosoureas
Dosage Forms & Strengths:
powder for injection
100mg
Wafer, Implant
7.7mg
150 - 200
mg
Intravenous (IV)
as a single dose for at least six weeks
Or divided into daily injections as a dose of 75-100 mg/m2 given IV for every two days
150 - 200
mg/m^2
Intravenous (IV)
as a single dose for at least six weeks
Or divided into daily injections as a dose of 75-100 mg/m2 given IV for every two days
150 - 200
mg/m^2
Intravenous (IV)
as a single dose for at least six weeks
Or divided into daily injections as a dose of 75-100 mg/m2 given IV for every two days
10
mg
Topical
once daily for 7–14 weeks and maximum continue up to 17 weeks, after six weeks, if there is an inadequate response, then the second course of topical therapy is administered with a dose of 20 mg once daily for 4 to 8 weeks until it is tolerable
7.7 mg 8 wafers i.e., 61.6 mg of total dose implanted intracranially
7.7 mg 8 wafers i.e., 61.6 mg of total dose implanted intracranially
may diminish the serum concentration of primidone
when both the drugs are combined, the metabolism of carmustine increases
when both the drugs are combined, the risk or severity of adverse effects increases
when both the drugs are combined, the risk or severity of infection increases
when both the drugs are combined, the metabolism of carmustine increases
when both the drugs are combined, it may increase the myelosuppressive activities of carmustine
when both the drugs are combined, the risk or severity of adverse effects increases
when both the drugs are combined, the risk or severity of neutropenia increases
when both the drugs are combined, carmustine may decrease the renal secretion of deferiprone and result in an increased serum level
when both the drugs are combined, carmustine reduces the effects of the vaccine by immunosuppressive effects and leads to the risk of infection
when both the drugs are combined, the metabolism of carmustine increases
when both the drugs are combined, carmustine increases the immunosuppressive effects of fingolimod
when both the drugs are combined, the metabolism of carmustine increases
when both the drugs are combined, the metabolism of carmustine increases
influenza virus vaccine h n live
when both the drugs are combined, carmustine decreases the effects of vaccine live by antagonism
when both the drugs are combined, the risk or severity of adverse effects increases
when both the drugs are combined, the therapeutic efficacy of the measles virus vaccine decreases
when both the drugs are combined, the therapeutic efficacy of the mumps virus vaccine decreases
when both the drugs are combined, the metabolism of carmustine decreases
when both the drugs are combined, the risk or severity of adverse effects increases
when both the drugs are combined, the risk or severity of adverse effects increases
when both the drugs are combined, the risk or severity of adverse effects increases
when both the drugs are combined, the therapeutic efficacy of the rotavirus vaccine decreases
when both the drugs are combined, the risk or severity of infection increases
when both the drugs are combined, the risk or severity of adverse effects increases
when both the drugs are combined, the therapeutic efficacy of the smallpox vaccine decreases
when both the drugs are combined, the serum concentration of carmustine decreases
when both the drugs are combined, the risk or severity of adverse effects decreases
when both the drugs are combined, the risk or severity of adverse effects increases
when both the drugs are combined, carmustine increases the immunosuppressive effects of tofacitinib
when both the drugs are combined, the therapeutic efficacy of the typhoid vaccine decreases
when both the drugs are combined, the risk or severity of adverse effects increases
when both the drugs are combined, the risk or severity of infection increases
when both the drugs are combined, the risk or severity of adverse effects increases
when both the drugs are combined, the risk or severity of infection increases
varicella zoster vaccine (recombinant)
when both the drugs are combined, the therapeutic efficacy of varicella-zoster vaccine (recombinant) decreases
when both the drugs are combined, the risk or severity of infection increases
when both the drugs are combined, the risk or severity of adverse effects increases
when both the drugs are combined, the risk or severity of adverse effects increases
when both the drugs are combined, the risk or severity of adverse effects increases
when both the drugs are combined, the metabolism of carmustine increases
when both the drugs are combined, the risk or severity of adverse effects increases
when both the drugs are combined, the risk or severity of adverse effects increases
when both the drugs are combined, the risk or severity of adverse effects increases
when both the drugs are combined, the risk or severity of adverse effects increases
when both the drugs are combined, the risk or severity of adverse effects increases
when both the drugs are combined, the metabolism of carmustine increases
when both the drugs are combined, the metabolism of carmustine decreases
when both the drugs are combined, the risk or severity of adverse effects decreases
when both the drugs are combined, the risk or severity of adverse effects increases
when both the drugs are combined, the risk or severity of adverse effects increases
when both the drugs are combined, the therapeutic efficacy of the cholera vaccine decreases
when both the drugs are combined, the risk or severity of adverse effects increases
when both the drugs are combined, the risk or severity of adverse effects increases
when both the drugs are combined, the risk or severity of adverse effects increases
when both the drugs are combined, the risk or severity of adverse effects increases
